Insight Molecular Diagnostics Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
58
- Stock Symbol
-
IMDX
- Investments
-
5
- Share Price
-
$2.14
- (As of Friday Closing)
Insight Molecular Diagnostics General Information
Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Contact Information
Website
www.imdxinc.comCorporate Office
- 2 International Plaza Drive
- Suite 510
- Nashville, TN 37217
- United States
Corporate Office
- 2 International Plaza Drive
- Suite 510
- Nashville, TN 37217
- United States
Insight Molecular Diagnostics Timeline
Insight Molecular Diagnostics Stock Performance
As of 13-Nov-2026, Insight Molecular Diagnostics’s stock price is $2.14. Its current market cap is $70M with 32.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.14 | $2.31 | $2.07 - $7.92 | $70M | 32.7M | 221K | -$1.50 |
Insight Molecular Diagnostics Financials Summary
As of 30-Jun-2026, Insight Molecular Diagnostics has a trailing 12-month revenue of $1.67M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 165,380 | 199,418 | 40,696 | 14,425 |
| Revenue | 1,670 | 4,055 | 1,881 | 1,503 |
| EBITDA | (46,818) | (47,906) | (58,991) | (23,123) |
| Net Income | (49,359) | (50,222) | (60,663) | (27,781) |
| Total Assets | 29,443 | 25,756 | 35,081 | 74,892 |
| Total Debt | 2,625 | 3,497 | 3,664 | 2,869 |
Insight Molecular Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Insight Molecular Diagnostics Comparisons
Industry
Financing
Details
Insight Molecular Diagnostics Competitors (22)
One of Insight Molecular Diagnostics’s 22 competitors is HTG Molecular Diagnostics, a Formerly VC-backed company based in Tucson, AZ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| HTG Molecular Diagnostics | Formerly VC-backed | Tucson, AZ | ||||
| BioGenex Laboratories | Corporation | Fremont, CA | ||||
| RareCyte | Venture Capital-Backed | Seattle, WA | ||||
| Oncimmune | Formerly VC-backed | Cambridge, MA | ||||
| Precipio | Formerly VC-backed | New Haven, CT |
Insight Molecular Diagnostics Patents
Insight Molecular Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023216680-A1 | Classifying tumors and predicting responsiveness | Pending | 02-Feb-2022 | ||
| EP-4473313-A2 | Classifying tumors and predicting responsiveness | Pending | 02-Feb-2022 | ||
| EP-4473313-A4 | Classifying tumors and predicting responsiveness | Pending | 02-Feb-2022 | ||
| US-20250140406-A1 | Classifying tumors and predicting responsiveness | Pending | 02-Feb-2022 | ||
| WO-2023150194-A2 | Classifying tumors and predicting responsiveness | Inactive | 02-Feb-2022 | G16H50/20 |
Insight Molecular Diagnostics Signals
Insight Molecular Diagnostics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Insight Molecular Diagnostics Investments & Acquisitions (5)
Insight Molecular Diagnostics’s most recent deal was a Merger/Acquisition with Chronix Biomedical for . The deal was made on 19-Apr-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Chronix Biomedical | 19-Apr-2021 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Riskreveal | 25-Feb-2021 | Merger/Acquisition | Diagnostic Equipment | ||
| Insight Genetics | 31-Jan-2020 | Merger/Acquisition | Other Devices and Supplies | ||
| Riskreveal | 05-Sep-2019 | Secondary Transaction - Private | Diagnostic Equipment | ||
| Cell Targeting | 28-Jan-2011 | Merger/Acquisition | Biotechnology |
Insight Molecular Diagnostics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.97 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Insight Molecular Diagnostics FAQs
-
When was Insight Molecular Diagnostics founded?
Insight Molecular Diagnostics was founded in 2009.
-
Where is Insight Molecular Diagnostics headquartered?
Insight Molecular Diagnostics is headquartered in Nashville, TN.
-
What is the size of Insight Molecular Diagnostics?
Insight Molecular Diagnostics has 58 total employees.
-
What industry is Insight Molecular Diagnostics in?
Insight Molecular Diagnostics’s primary industry is Diagnostic Equipment.
-
Is Insight Molecular Diagnostics a private or public company?
Insight Molecular Diagnostics is a Public company.
-
What is Insight Molecular Diagnostics’s stock symbol?
The ticker symbol for Insight Molecular Diagnostics is IMDX.
-
What is the current stock price of Insight Molecular Diagnostics?
As of 13-Nov-2026 the stock price of Insight Molecular Diagnostics is $2.14.
-
What is the current market cap of Insight Molecular Diagnostics?
The current market capitalization of Insight Molecular Diagnostics is $70M.
-
What is Insight Molecular Diagnostics’s current revenue?
The trailing twelve month revenue for Insight Molecular Diagnostics is $1.67M.
-
Who are Insight Molecular Diagnostics’s competitors?
HTG Molecular Diagnostics, BioGenex Laboratories, RareCyte, Oncimmune, and Precipio are some of the 22 competitors of Insight Molecular Diagnostics.
-
What is Insight Molecular Diagnostics’s annual earnings per share (EPS)?
Insight Molecular Diagnostics’s EPS for 12 months was -$1.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process